http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102038950-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3f1130e23cff1328c0ae14101d12103f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-116 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate | 2009-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b902c4e9786ae15575f94367f0efb992 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02699f6c2d4d61f845003ee8665c301d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c6b1081fe99b07c2de16745d2a5c8ce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_579ec9654fe53a29f36bee693a7e70da http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e3a4f64dcaa1925825f60ed2816dbba |
| publicationDate | 2013-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102038950-B |
| titleOfInvention | Novel immune adjuvant and vaccine containing same |
| abstract | The invention relates to a novel immune adjuvant and a vaccine containing the same. The main ingredient of the immune adjuvant is recombinant human calcineurin B subunit. The immune vaccine at least contains the immune adjuvant. The purification and preparation method of the immune adjuvant is simple, easy to implement, high in yield and low in cost. And the immune adjuvant is very stable and thermal resistant and therefore can be stored for a long time. After being simply mixed with antigen, the immune adjuvant can directly and effectively act on animals and people. In addition, the gene sequence of the immune adjuvant is basically consistent with that of human and animals (such as rats and mice) and thus has high homology with that of human and animals. The coherence between the conclusion of animal experiments and the conclusion of human body experiments is high. |
| priorityDate | 2009-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 101.